Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
SHPL primarily manufactures, sells, and distributes its own-brand prescription medicines in China, predominantly for cardiovascular diseases.On Wednesday, Hutchmed (China) Limited (NASDAQ:HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 billion) in cash to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd.
周三，和黄医药（中国）有限公司（纳斯达克股票代码：HCM）签订了两项协议，以约6.08亿美元（人民币44.78元）的现金将其在上海和记制药有限公司（SHPL）45％的股权剥离给GP Health Service Capital有限公司和上海医药控股有限公司。
Hutchmed has been exploring opportunities to monetize the underlying value of SHPL, a non-core, non-consolidated joint venture.
和黄医药一直在探索将SHPL（一家非核心、非合并的合资企业）的潜在价值货币化的机会。
These transactions would allow Hutchmed to focus on its core business of discovering, developing, and commercializing novel therapies for cancers and immunological diseases, including advancing its next-generation antibody-targeted therapy conjugate programs.
这些交易将使和黄医药能够专注于其核心业务，即发现、开发和商业化癌症和免疫疾病的新疗法，包括推进其下一代抗体靶向疗法偶联物项目。
SHPL primarily manufactures, sells, and distributes its own-brand prescription medicines in China, predominantly for cardiovascular diseases.
SHPL主要在中国制造、销售和分销自有品牌处方药，主要用于心血管疾病。
SHPL is a 50:50 joint venture established between Hutchmed and Shanghai Pharma in 2001.
SHPL 是和黄医药与上海制药于 2001 年成立的 50:50 的合资企业。
In 2023, the consolidated net income attributable to Hutchmed from SHPL was $47.4 million. HUTCHMED does not consolidate revenue from SHPL.
2023年，SHPL归属于和黄医药的合并净收益为4,740万美元。和黄医药不合并来自SHPL的收入。
Hutchmed plans to invest the proceeds from these transactions to further develop its internal pipeline and advance its core business strategy.
和黄医药计划将这些交易的收益投资于进一步发展其内部渠道并推进其核心业务战略。
Hutchmed plans to move the first of these antibody-targeted therapy conjugates into clinical trials in the second half of 2025.
和记医药计划在2025年下半年将第一批抗体靶向疗法偶联物转入临床试验。
Before the transactions, Hutchmed and Shanghai Pharma each hold a 50% equity interest in SHPL. GP Health Service Capital has agreed to acquire a 35% equity interest for approximately $473 million in cash, and Shanghai Pharma will acquire a 10% equity interest for approximately $135 million in cash.
交易前，和黄医药和上海医药各持有SHPL的50％股权。GP Health Service Capital已同意以约4.73亿美元的现金收购35％的股权，上海制药将以约1.35亿美元的现金收购10％的股权。
After the transactions, the investors will hold a 60% equity interest in SHPL. Out of its 35%, GP Health Service Capital retains the right to designate a third-party investment fund to acquire up to a 10% equity interest in SHPL.
交易完成后，投资者将持有SHPL60％的股权。在其35％中，GP Health Service Capital保留指定第三方投资基金收购SHPL高达10％的股权的权利。
Hutchmed will retain a 5% equity interest in SHPL after the transactions.
交易完成后，和黄医药将保留SHPL的5％股权。
Hutchmed expects to record a gain on disposal of approximately $477 million before taxation.
和黄医药预计将录得约4.77亿美元的税前处置收益。
On Wednesday, Hutchmed announced that the China National Medical Products Administration accepted and granted priority review of the New Drug Application for the combination of Orpathys (savolitinib) and Tagrisso (osimertinib) for locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression.
和黄医药周三宣布，中国国家药品监督管理局接受并批准了奥帕希斯（赛沃利替尼）和泰瑞索（奥美替尼）联合治疗局部晚期或转移性表皮生长因子受体突变阳性非小细胞肺癌的新药申请，并在疾病进展后进行MeT扩增。
The acceptance also triggers a milestone payment from AstraZeneca plc (NASDAQ:AZN).
接受还触发了阿斯利康公司（纳斯达克股票代码：AZN）的里程碑式付款。
Price Action: At last check on Wednesday, HCM stock was up 7.98% at $15.56 during the premarket session.
价格走势：在周三的最后一次检查中，HCm股价在盘前交易时段上涨7.98％，至15.56美元。
- Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
- 为什么专注于脑癌的Kazia Therapeutics股票周二交易价格走低？